3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
6
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
37
Carcinoma, Non-Small-Cell Lung
30
Prostatic Neoplasms
20
Neoplasm Metastasis
19
Breast Neoplasms
19
Colorectal Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
14
Leukemia, Myeloid, Acute
13
Stomach Neoplasms
12
Ovarian Neoplasms
12
Melanoma
12
Lung Neoplasms
12
Carcinoma, Hepatocellular
12
Recurrence
11
Hematologic Neoplasms
10
Endometrial Neoplasms
10
Rectal Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Pancreatic Neoplasms
9
Lymphoma
9
Head and Neck Neoplasms
9
Myasthenia Gravis
8
Leukemia
8
Fatigue
8
Urinary Bladder Neoplasms
7
Neoplasms by Site
7
Neoplasms by Histologic Type
7
Lymphoma, Large B-Cell, Diffuse
7
Glioblastoma
7
Colonic Neoplasms
6
Interventions
Standard of Care
1
Olanzapine
1
Enteral Nutrition
1
Cyproheptadine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Muscular Atrophy
×
1 year
×
Clear all
NCT06175273
2025-09-18
POINT
University of Kentucky
Phase 2/3
Completed
19 enrolled